BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of nonerosive reflux disease in Asia. World J Gastroenterol 2008; 14(20): 3123-3128 [PMID: 18506915 DOI: 10.3748/wjg.14.3123] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, Sakaguchi Y, Nakayama C, Konno-Shimizu M, Matsuda R, Mochizuki S, Asada-Hirayama I, Tsuji Y, Kodashima S, Ono S, Niimi K, Mitsushima T, Koike K. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013;8:e69891. [PMID: 23922844 DOI: 10.1371/journal.pone.0069891] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
2 Morita T, Furuta K, Adachi K, Ohara S, Tanimura T, Koshino K, Uemura T, Naora K, Kinoshita Y. Effects of Rikkunshito (TJ-43) on Esophageal Motor Function and Gastroesophageal Reflux. J Neurogastroenterol Motil 2012;18:181-6. [PMID: 22523727 DOI: 10.5056/jnm.2012.18.2.181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
3 Kimura Y, Sugiura M, Kato T, Makino N, Ohmae Y, Kishimoto S. Value of barium swallow studies in predicting the response to rabeprazole in elderly patients with laryngopharyngeal reflux disease and nonerosive reflux disease in particular. Ann Otol Rhinol Laryngol 2010;119:631-5. [PMID: 21033032 DOI: 10.1177/000348941011900911] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Miwa H, Koseki J, Oshima T, Kondo T, Tomita T, Watari J, Matsumoto T, Hattori T, Kubota K, Iizuka S. Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa. J Gastroenterol. 2010;45:478-487. [PMID: 20016992 DOI: 10.1007/s00535-009-0180-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
5 Ha NR, Lee HL, Lee OY, Yoon BC, Choi HS, Hahm JS, Ahn YH, Koh DH. Differences in clinical characteristics between patients with non-erosive reflux disease and erosive esophagitis in Korea. J Korean Med Sci. 2010;25:1318-1322. [PMID: 20808675 DOI: 10.3346/jkms.2010.25.9.1318] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
6 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Kohata Y, Fujiwara Y, Machida H, Okazaki H, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Arakawa T. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring. J Gastroenterol Hepatol. 2012;27 Suppl 3:58-62. [PMID: 22486873 DOI: 10.1111/j.1440-1746.2012.07074.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
8 Miwa H, Oshima T, Tomita T, Kim Y, Hori K, Matsumoto T. Gastro-esophageal reflux disease: the recent trend in Japan. Clin J Gastroenterol 2008;1:133-8. [DOI: 10.1007/s12328-008-0039-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
9 Xiao J, Yang Y, Zhu Y, Qin Y, Li Y, Fu M, Zhai Z, Zhu L. Efficacy and Safety of Traditional Chinese Medicine on Nonerosive Reflux Disease: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2018;2018:1505394. [PMID: 29977310 DOI: 10.1155/2018/1505394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Uemura R, Murakami Y, Hashimoto A, Sawada A, Otani K, Taira K, Hosomi S, Nagami Y, Tanaka F, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Taguchi YH, Fujiwara Y. Expression of Serum Exosomal and Esophageal MicroRNA in Rat Reflux Esophagitis. Int J Mol Sci 2017;18:E1611. [PMID: 28757556 DOI: 10.3390/ijms18081611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Emiroglu HH, Sokucu S, Suoglu OD, Gulluoglu M, Gokce S. Is there a relationship between Helicobacter pylori infection and erosive reflux disease in children? Acta Paediatr 2010;99:121-5. [PMID: 19785631 DOI: 10.1111/j.1651-2227.2009.01512.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Marakhouski KY, Karaseva GA, Ulasivich DN, Marakhouski YK. Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease. Clin Med Insights Gastroenterol 2017;10:1179552217709456. [PMID: 28607547 DOI: 10.1177/1179552217709456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Wang PC, Hsu CS, Tseng TC, Hsieh TC, Chen CH, Su WC, Lin HH, Wang CC. Male sex, hiatus hernia, and Helicobacter pylori infection associated with asymptomatic erosive esophagitis. J Gastroenterol Hepatol. 2012;27:586-591. [PMID: 21871022 DOI: 10.1111/j.1440-1746.2011.06881.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
14 Sakata Y, Tominaga K, Kato M, Takeda H, Shimoyama Y, Takeuchi T, Iwakiri R, Furuta K, Sakurai K, Odaka T. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito. BMC Gastroenterol. 2014;14:116. [PMID: 24990161 DOI: 10.1186/1471-230x-14-116] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
15 Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol. 2009;24:537-546. [PMID: 19220673 DOI: 10.1111/j.1440-1746.2009.05780.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
16 Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20:2412-2419. [PMID: 24605040 DOI: org/10.3748/wjg.v20.i9.2412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Koshino K, Adachi K, Furuta K, Ohara S, Morita T, Nakata S, Tanimura T, Miki M, Kinoshita Y. Effects of mosapride on esophageal functions and gastroesophageal reflux. J Gastroenterol Hepatol. 2010;25:1066-1071. [PMID: 20594220 DOI: 10.1111/j.1440-1746.2010.06280.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
18 Tominaga K, Arakawa T. Clinical application of kampo medicine (rikkunshito) for common and/or intractable symptoms of the gastrointestinal tract. Front Pharmacol 2015;6:7. [PMID: 25688209 DOI: 10.3389/fphar.2015.00007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
19 Yang XJ, Jiang HM, Hou XH, Song J. Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life. World J Gastroenterol 2015; 21(14): 4302-4309 [PMID: 25892882 DOI: 10.3748/wjg.v21.i14.4302] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
20 Hiyama T, Matsuo K, Urabe Y, Fukuhara T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol. 2009;24:1326-1332. [PMID: 19702900 DOI: 10.1111/j.1440-1746.2009.05879.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
21 Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, Umegaki E, Higuchi K, Kusano M, Arakawa T. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284-292. [PMID: 22081052 DOI: 10.1007/s00535-011-0488-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
22 Kohata Y, Fujiwara Y, Yamagami H, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Arakawa T. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease. J Gastroenterol Hepatol 2015;30 Suppl 1:36-40. [PMID: 25827802 DOI: 10.1111/jgh.12743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
23 Kamei J, Hayashi S, Sakai A, Nakanishi Y, Kai M, Ikegami M, Ikeda H. Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NFκB) phosphorylation in spinal cord of mice. PLoS One 2017;12:e0171819. [PMID: 28182729 DOI: 10.1371/journal.pone.0171819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tsai MK, Ding HJ, Lai HC, Yen KY, Li CI, Lin YY, Cheng KY, Wang KB, Kao CH. Detection of gastroesophageal reflux esophagitis using 2-fluoro-2-deoxy-d-glucose positron emission tomography. ScientificWorldJournal 2012;2012:702803. [PMID: 22919350 DOI: 10.1100/2012/702803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
25 Kondo T, Oshima T, Koseki J, Hattori T, Kase Y, Tomita T, Fukui H, Watari J, Miwa H. Effect of rikkunshito on the expression of substance P and CGRP in dorsal root ganglion neurons and voluntary movement in rats with experimental reflux esophagitis. Neurogastroenterol Motil. 2014;26:913-921. [PMID: 24712488 DOI: 10.1111/nmo.12342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
26 Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, Umegaki E, Higuchi K, Kusano M, Arakawa T. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284-292. [PMID: 22081052 DOI: 10.1007/s0053-011-0488-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: A meta-analysis. World J Gastroenterol 2014; 20(9): 2412-2419 [PMID: 24605040 DOI: 10.3748/wjg.v20.i9.2412] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
28 Tominaga K, Arakawa T. Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application. J Gastroenterol. 2013;48:452-462. [PMID: 23503839 DOI: 10.1007/s00535-013-0788-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
29 Tominaga K, Kato M, Takeda H, Shimoyama Y, Umegaki E, Iwakiri R, Furuta K, Sakurai K, Odaka T, Kusunoki H, Nagahara A, Iwakiri K, Furuta T, Murakami K, Miwa H, Kinoshita Y, Haruma K, Takahashi S, Watanabe S, Higuchi K, Kusano M, Fujimoto K, Arakawa T; G-PRIDE Study Group. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol 2014;49:1392-405. [DOI: 10.1007/s00535-013-0896-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
30 Jeon HK, Kim GH, Lee MW, Joo DC, Lee BE. Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease. JCM 2022;11:1965. [DOI: 10.3390/jcm11071965] [Reference Citation Analysis]
31 Niu XP, Yu BP, Wang YD, Han Z, Liu SF, He CY, Zhang GZ, Wu WC. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol 2013; 19(20): 3124-3129 [PMID: 23716993 DOI: 10.3748/wjg.v19.i20.3124] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
32 Mizuki A, Tatemichi M, Sakakibara T, Miura Y, Zeki S, Ohata M, Matsuo K, Kawamura F, Nagata H. A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life. Curr Ther Res Clin Exp 2016;79:1-7. [PMID: 28066515 DOI: 10.1016/j.curtheres.2016.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Yamaji Y, Isomura Y, Yoshida S, Yamada A, Hirata Y, Koike K. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. J Dig Dis 2014;15:469-76. [PMID: 24957863 DOI: 10.1111/1751-2980.12167] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]